Far from being a money saver, the generic medicines market has cost the NHS an additional £76m over the past two years.
Researchers around the world are working at record speed to find the best ways to treat and prevent COVID-19, from investigating the possibility of repurposing existing drugs to searching for novel therapies against the virus.
Work towards a COVID-19 vaccine is progressing rapidly and new information is emerging every day. Here we aim to summarise the most important details of COVID-19 vaccine development from a pharmacy perspective.
The latest information about the novel coronavirus identified in Wuhan, China, and advice on how pharmacists can help concerned patients and the public.
The early access to medicines scheme has been running for six years, but has it had the desired impact of ensuring the sickest patients are spared the wait for the most promising treatments, or is it failing to live up to expectations?
Universal foundation training for pharmacists is being introduced sooner than expected, with an interim foundation programme launched this autumn and a one-year foundation scheme set to replace the current preregistration year from July 2021.
Most people recover from COVID-19 within two weeks; however, early figures suggest that around one in seven people have symptoms lasting for at least four weeks, and a smaller proportion are sick for months.
The COVID-19 pandemic is putting a lot of additional pressure on an already underfunded community pharmacy sector, resulting in many pharmacies closing down.
Urinary tract infections are the second most common reason for prescribing an antibiotic and, with antimicrobial stewardship a priority for the government, the stakes for accurate diagnosis are being raised ever higher.
The UK government has ordered 340 million doses of COVID-19 vaccines from several manufacturers, with the hope that at least one will prove successful in large clinical trials over the next few months. However, there are no guarantees and some of the strategies are not without their challenges.
As cases of COVID-19 start to rise again in the UK, what can pharmacy staff do to prepare for a potential second surge of infections?
With antibiotic resistance set to cost 10 million lives per year by 2050, there is a renaissance of interest in the potential of bacteriophages to be the next generation of bacteria killers.
The coronavirus pandemic has been a huge challenge, but it has revolutionised pharmacy practice in some positive ways. In the third of a three-part series, we ask community pharmacists which changes they want to retain.
The whole of the NHS is gearing up for what ministers call the “biggest flu vaccination programme in history”, but it is still unclear what role community pharmacy will be able to play.
Homeless people face many barriers when it comes to accessing basic healthcare and, as a result, are only likely to live until their mid-40s. Some pharmacists are working to take care out onto the streets to help give these people a chance at a better life.
The coronavirus pandemic has been a huge challenge, but it has revolutionised pharmacy practice in some positive ways. In the second feature of a three-part series, we ask GP pharmacists which changes they want to retain.
Testing for COVID-19 antibodies has been riddled with government miscommunication and a lack of clarity, but here is what we know so far.
The prime minister has said that he will put a “tiger in the tank” of Brexit talks, but what should the pharmacy profession look out for in any deal that is eventually agreed?
Drugs in space: the pharmacy orbiting the Earth Subscription
Researchers are busy developing pharmaceutical solutions for astronauts, but that extraterrestrial research could also have implications for how medicines are delivered on Earth.
The COVID-19 pandemic has been a huge challenge, but it has revolutionised pharmacy practice in some positive ways. In the first of a three-part series, we ask hospital pharmacists which changes they want to retain.
The COVID-19 pandemic has forced radical changes to how the 2020 class of preregistration trainees will transition into their careers.
The vast majority of people with a penicillin allergy label are, in fact, not allergic, leading to significant healthcare implications. Experts say it is now time for a national “de-labelling” drive to help conserve vital antibiotics.
The under-representation of women in clinical trials is slowly being addressed, but we cannot move towards truly personalised healthcare unless we have an equal balance of the sexes in all new medicine trials.
Community pharmacy is providing a vital connection to support older and clinically vulnerable patients during lockdown in the UK.
The temporary field hospitals set up across the UK to help the NHS cope during the COVID-19 pandemic have given hospital pharmacists a unique opportunity for valuable learning and teamwork.
There has been a surge in demand for gender identity services in the UK over the past five years. Although the current role of pharmacists is limited, their potential contribution within a multidisciplinary team supporting transgender patients is beginning to emerge.
When Public Health England published new guidance on the use of personal protective equipment during the COVID-19 pandemic on 2 April 2020, pharmacy’s representative bodies thought the battle was won.
As researchers around the globe drop everything to find a treatment for COVID-19, we look at the likely frontrunners for managing this deadly disease.
Incidence of sexually transmitted infections is increasing and antimicrobial resistance is adding fuel to the fire, particularly in the case of gonorrhoea. In response, researchers are working on three major strategies to help reduce its spread and maintain susceptibility to antibiotics.
Going against type: the new class of cancer therapies targeting mutations rather than tissuesSubscription
‘Tumour agnostic’ drugs offer a more effective and tolerable therapy for a wide range of people with cancer, so why has the NHS rejected its first one?